As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.
The Indian pharmaceutical industry witnessed a mixed year in 2014. Even as the USFDA kept the entire sector on its toes, the Sun Pharma - Ranbaxy deal changed the dynamics of the market forever.
As 2014 comes to an end, Surajit Pal of Prabhudas Lilladher shares his outlook on the year that was and the possible trends for 2015.
Although Sun-Ranbaxy pact will see rationalisation of workforce, Sun Pharma's margins could reduce to 30-32 percent post its merger, he says in an interview with CNBC-TV18's Sonia Shenoy and Ekta Batra.
According to him, in the second half of 2015, number of patents may reduce for Lupin .
Meanwhile, the plunge in Russian rouble may impact companies such as DRL and Glenmark from the pharmaceutical space.
Transcript to follow shortly
Sun Pharma stock price
On December 29, 2014, at 14:15 hrs Sun Pharmaceutical Industries was quoting at Rs 818.20, up Rs 7.00, or 0.86 percent. The 52-week high of the share was Rs 932.00 and the 52-week low was Rs 552.50.
The latest book value of the company is Rs 35.77 per share. At current value, the price-to-book value of the company was 22.87.
Anda sedang membaca artikel tentang
Sun's margins may reduce to 30-32% post merger: Surajit Pal
Dengan url
https://kesehatanda.blogspot.com/2014/12/suns-margins-may-reduce-to-30-32-post.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Sun's margins may reduce to 30-32% post merger: Surajit Pal
namun jangan lupa untuk meletakkan link
Sun's margins may reduce to 30-32% post merger: Surajit Pal
sebagai sumbernya
0 komentar:
Posting Komentar